Go Pro
→ Major Buy Alert Issued for August 31st (From TradeSmith) (Ad)tc pixel Free LABT Stock Alerts

Lakewood-Amedex Biotherapeutics (LABT) Competitors

Lakewood-Amedex Biotherapeutics logo
$2.16 -0.11 (-4.85%)
Closing price 08/17/2026 04:00 PM Eastern
Extended Trading
$2.22 +0.06 (+2.78%)
As of 04:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

LABT vs. KZIA, LGVN, ALLR, NEUP, and QNTM

Should you buy Lakewood-Amedex Biotherapeutics stock or one of its competitors? Lakewood-Amedex Biotherapeutics's main competitors and comparable companies include Novogen (KZIA), Longeveron (LGVN), Allarity Therapeutics (ALLR), Neuphoria Therapeutics (NEUP), and Quantum Biopharma (QNTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lakewood-Amedex Biotherapeutics compare to Novogen?

Novogen (NASDAQ:KZIA) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Novogen presently has a consensus target price of $26.33, indicating a potential upside of 94.20%. Given Novogen's stronger consensus rating and higher possible upside, equities analysts clearly believe Novogen is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novogen
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Company Net Margins Return on Equity Return on Assets
NovogenN/A N/A N/A
Lakewood-Amedex Biotherapeutics N/A N/A N/A

In the previous week, Novogen and Novogen both had 3 articles in the media. Novogen's average media sentiment score of 0.96 beat Lakewood-Amedex Biotherapeutics' score of 0.75 indicating that Novogen is being referred to more favorably in the media.

Company Overall Sentiment
Novogen Positive
Lakewood-Amedex Biotherapeutics Positive

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than Novogen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novogen$42K533.68-$13.41MN/AN/A
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$2.00N/A

30.9% of Novogen shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Novogen beats Lakewood-Amedex Biotherapeutics on 6 of the 8 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Longeveron?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

In the previous week, Longeveron had 3 more articles in the media than Lakewood-Amedex Biotherapeutics. MarketBeat recorded 6 mentions for Longeveron and 3 mentions for Lakewood-Amedex Biotherapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.75 beat Longeveron's score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Positive
Longeveron Neutral

Longeveron has a consensus price target of $8.00, indicating a potential upside of 875.61%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Longeveron
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Longeveron. Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$2.00N/A
Longeveron$1.20M21.29-$22.70M-$0.99N/A

10.0% of Longeveron shares are owned by institutional investors. 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lakewood-Amedex Biotherapeutics has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Longeveron -1,977.59%-223.19%-150.20%

Summary

Longeveron beats Lakewood-Amedex Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allarity Therapeutics$320K66.62-$11.23M-$0.78N/A
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$2.00N/A

11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Allarity TherapeuticsN/A -128.66% -50.02%
Lakewood-Amedex Biotherapeutics N/A N/A N/A

In the previous week, Allarity Therapeutics had 3 more articles in the media than Lakewood-Amedex Biotherapeutics. MarketBeat recorded 6 mentions for Allarity Therapeutics and 3 mentions for Lakewood-Amedex Biotherapeutics. Allarity Therapeutics' average media sentiment score of 0.81 beat Lakewood-Amedex Biotherapeutics' score of 0.75 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Allarity Therapeutics Positive
Lakewood-Amedex Biotherapeutics Positive

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 664.93%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allarity Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Allarity Therapeutics beats Lakewood-Amedex Biotherapeutics on 8 of the 13 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

In the previous week, Neuphoria Therapeutics and Neuphoria Therapeutics both had 3 articles in the media. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.75 beat Neuphoria Therapeutics' score of 0.49 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Neuphoria Therapeutics Neutral
Lakewood-Amedex Biotherapeutics Positive

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuphoria TherapeuticsN/A -76.93% -54.76%
Lakewood-Amedex Biotherapeutics N/A N/A N/A

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Neuphoria Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 445.45%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Neuphoria Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Neuphoria Therapeutics has higher revenue and earnings than Lakewood-Amedex Biotherapeutics. Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuphoria Therapeutics$15.65M1.33-$370K-$11.06N/A
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$2.00N/A

Summary

Neuphoria Therapeutics beats Lakewood-Amedex Biotherapeutics on 7 of the 12 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Quantum Biopharma?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

In the previous week, Quantum Biopharma had 5 more articles in the media than Lakewood-Amedex Biotherapeutics. MarketBeat recorded 8 mentions for Quantum Biopharma and 3 mentions for Lakewood-Amedex Biotherapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.75 beat Quantum Biopharma's score of -0.16 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Positive
Quantum Biopharma Neutral

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Quantum Biopharma N/A -582.23%-184.20%

1.2% of Quantum Biopharma shares are held by institutional investors. 5.4% of Lakewood-Amedex Biotherapeutics shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Quantum Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$2.00N/A
Quantum BiopharmaN/AN/A-$26.17M-$5.49N/A

Summary

Lakewood-Amedex Biotherapeutics beats Quantum Biopharma on 5 of the 9 factors compared between the two stocks.

Get Lakewood-Amedex Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LABT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LABT vs. The Competition

Export
MetricLakewood-Amedex BiotherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.38M$3.73B$7.03B$13.06B
Dividend YieldN/A3.69%2.56%10.62%
P/E Ratio-1.0811.49270.8625.39
Price / SalesN/A1,290.85602.9192.24
Price / CashN/A45.1128.8738.47
Price / BookN/A17.3811.176.51
Net Income-$3.85M-$13.18M$3.45B$347.22M
7 Day Performance-8.47%0.85%0.63%1.27%
1 Month Performance14.29%2.56%2.10%2.72%
1 Year PerformanceN/A54.00%61.61%21.85%

Lakewood-Amedex Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LABT
Lakewood-Amedex Biotherapeutics
0.2342 of 5 stars		$2.16
-4.8%		N/AN/A$5.38MN/AN/A5
KZIA
Novogen
3.5161 of 5 stars		$13.52
+2.3%		$26.33
+94.8%		+68.9%$21.84M$42KN/A12
LGVN
Longeveron
1.4488 of 5 stars		$0.74
+6.1%		$8.00
+981.2%		+7.9%$21.73M$1.20MN/A20
ALLR
Allarity Therapeutics
2.6296 of 5 stars		$1.37
+0.7%		$10.25
+648.2%		+39.9%$21.64M$320KN/A10
NEUP
Neuphoria Therapeutics
2.379 of 5 stars		$3.87
+1.0%		$21.00
+442.6%		-52.5%$20.70M$15.65MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LABT) was last updated on 8/18/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Iran War: What Happened at 1:11 P.M. Outside D.C.?
A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...
Banyan Hill Publishing | Sponsoredtc pixel
Gold Miners Post Record Cash Flow Even as Prices Pull Back
The four largest gold miners are generating record free cash flow, even with gold pulling back from recent hig...
Golden Portfolio | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
A Wall Street veteran shares two simple trading rules
A self-described Market Wizard says two simple rules, refined over decades on Wall Street, form the basis of h...
Brownstone Research | Sponsoredtc pixel
19 Factories. One AI Brain. One Hidden Stock.
A little-known aerospace manufacturer has linked 19 factories worldwide into a single AI-ready data system, dr...
The Oxford Club | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel